Company Profiles

driven by the PitchBook Platform

Theraclone Sciences

Description

Developer of therapeutic antibodies for the treatment of cancer and infectious diseases. The company offers a discovery platform to screen and identify the rare antibodies produced naturally by human memory B cells in response to disease-causing agents or conditions which are used to treat cancer, influenza and other diseases.

2004

Founded

PRIVATE

Status

11-50

Employees

Series C

Latest Deal Type

$4.4M

Latest Deal Amount

$59.2M

Total Amount Raised

Description

Developer of therapeutic antibodies for the treatment of cancer and infectious diseases. The company offers a discovery platform to screen and identify the rare antibodies produced naturally by human memory B cells in response to disease-causing agents or conditions which are used to treat cancer, influenza and other diseases.

Website:

www.therac

Formerly Known As

Spaltudaq

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Drug Discovery
Other Healthcare

Primary Office

Seattle Life Sciences Building 1124 Columbia Street, Suite 300 Seattle, WA 98104United States +1 (206) 805-1600
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Theraclone Sciences's full profile, request a free trial.

Theraclone Sciences Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Theraclone Sciences Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Theraclone Sciences Investors (11)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
AcceleratorVenture CapitalMinority000 0000000 0000
Alexandria Real Estate EquitiesReal EstateMinority000 0000000 0000
Amgen VenturesCorporate Venture CapitalMinority000 0000000 0000
ARCH Venture PartnersVenture CapitalMinority000 0000000 0000
Canaan PartnersVenture CapitalMinority000 0000000 0000
Accelerator Venture Capital
Alexandria Real Estate Equities Real Estate
Amgen Ventures Corporate Venture Capital
ARCH Venture Partners Venture Capital
Canaan Partners Venture Capital

Theraclone Sciences Executive Team (5)

NameTitleBoard
Seat
Contact
Info
Clifford StocksChief Executive Officer & Board Member
Russ HawkinsonChief Financial Officer & Vice President
Kristine Swiderek Ph.DChief Scientific Officer
Aurelio BonaviaDirector, Biology
Po-Ying Chan-HuiSenior Director, Pharmacology
Clifford Stocks Chief Executive Officer & Board Member
Russ Hawkinson Chief Financial Officer & Vice President
Kristine Swiderek Ph.D Chief Scientific Officer
Aurelio Bonavia Director, Biology
Po-Ying Chan-Hui Senior Director, Pharmacology

Theraclone Sciences Board Members (7)

NameRepresentingRoleSinceContact
Info
Alexander RivesARCH Venture PartnersBoard Member000 0000
Christopher Mirabelli Ph.DHealthCare VenturesBoard Member000 0000
Clifford StocksTheraclone SciencesChief Executive Officer & Board Member000 0000
Steven Gillis Ph.DARCH Venture PartnersChairman000 0000
Wende HuttonCanaan PartnersBoard Member000 0000
Alexander Rives Board Member ARCH Venture Partners
Christopher Mirabelli Ph.D Board Member HealthCare Ventures
Clifford Stocks Chief Executive Officer & Board Member Theraclone Sciences
Steven Gillis Ph.D Chairman ARCH Venture Partners
Wende Hutton Board Member Canaan Partners
Request full access to PitchBook